Testimony Discusses How Company's Technique for Human Stem Cell Development May Advance Support for Stem Cell Research
Worcester, MA, September 6, 2006 -- Advanced Cell Technology, Inc. (OTCBB:ACTC.OB) today announced that Robert Lanza, M.D., Advanced Cell Technology's Vice President of Medical and Stem Cell Development, testified today before the Senate Labor, Health & Human Services and Education Appropriations Subcommittee. Dr. Lanza's testimony focused on support for wider availability of human embryonic stem cells for basic medical research. Dr. Lanza is the principle author of a paper published online (ahead of print) on August 23 in the peer-reviewed journal Nature, which described a technique for developing human embryonic stem cells with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). This technique is not harmful to embryos.
"Our hope is that the new method we described in Nature can be used to increase the number of cell lines that qualify for federal funding within the framework of existing U.S. laws and regulations,” Dr. Lanza said.”
William Caldwell, Advanced Cell Technology's Chief Executive Officer commented, "We believe our technology offers a significant forward step in the field of regenerative medicine and adds to the array of available technologies. Since Dr. Lanza testified here last year, we have progressed from applying the single-cell derivation technique from the mouse to the human. In that year alone, a million people died from diseases that could that could potentially be treated"and possibly cured�"using future stem cell therapies. We urge wider availability of cell lines for medical research.�”
About Advanced Cell Technology
Advanced Cell Technology, Inc. is a biotechnology company engaged in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports including the quarterly report on Form 10-QSB for the period ending June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Advanced Cell Technology, Inc.